Summary

Ranibizumab, an anti-VEGF antibody fragment that is designed for intraocular use in diabetic retinopathy (DR), led to rapid and sustained improvement in both vision and retinal anatomy, reduced progression of DR, and improved patient-reported function in the RISE and RIDE clinical trials.